Table of Content

1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for The Study
3. Executive Summary
4. Factors Affecting Market Growth
4.1. Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Cardiovascular Diseases and Rising Geriatric Population
4.2.2. Technological Advancements in Cardiac Biomarkers
4.2.3. Increasing Healthcare Expenditure
4.2.4. Inreasing Cardiovascular Disease Awareness Programs
4.3. Restraints
4.3.1. Limited Specificity and Sensitivity of Biomarkers
4.3.2. High Cost of Biomarker Testing
4.4. Opportunity
4.4.1. Introduction of Novel Biomarker Tests
4.4.2. Integration of Biomarkers in Point-of-Care Testing
4.5. Challenges
4.5.1. Alternative Diagnostic Technologies
4.6. Trends
4.6.1. Focus on Multi-Analyte Panels
4.7. Regulatory Analysis
4.8. Porter’s Five Forces Analysis
5. Cardiac Biomarkers Market Assessment?By Type
5.1. Overview
5.2. Troponin
5.3. Creatine Kinase Mb (Ck-Mb)
5.4. Myoglobin
5.5. B-Type Natriuretic Peptide (Bnp)
5.6. N-Terminal Pro-B-Type Natriuretic Peptide (Nt-Probnp)
5.7. Other Types
6. Cardiac Biomarkers Market Assessment?By Application
6.1. Overview
6.2. Myocardial Infarction
6.3. Acute Coronary Syndrome
6.4. Congestive Heart Failure
6.5. Other Applications
7. Cardiac Biomarkers Market Assessment?By End User
7.1. Overview
7.2. Laboratory Testing
7.3. Point-of-Care Testing
8. Cardiac Biomarkers Market Assessment–By Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. Uk
8.3.4. Italy
8.3.5. Spain
8.3.6. Switzerland
8.3.7. Rest of Europe (Roe)
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Rest of Asia-Pacific (Roapac)
8.5. Latin America
8.6. Middle East & Africa
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share/Ranking Analysis, By Key Players, 2023
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and Swot Analysis*)
10.1. F. Hoffman-La-Roche Ltd (Switzerland)
10.2. Bio-Rad Laboratories, Inc. (U.S.)
10.3. Abbott Laboratories (U.S.)
10.4. Thermo Fisher Scientific Inc. (U.S.)
10.5. Siemens Healthineer AG (Germany)
10.6. Danaher Corporation (U.S.)
10.7. bioMerieux SA (France)
10.8. Becton, Dickinson and Company (U.S.)
10.9. Life Diagnostics, Inc. (U.S.)
10.10. Creative Diagnostics (U.S.)
10.11. Randox Laboratories Ltd (U.K.)
10.12. QuidelOrtho Corporation (U.S.)
(Note: Swot Analysis* Will Be Provided of The Top 5 Companies)
11. Appendix
11.1. Available Customization
11.2. Related Reports



List of Figures

Figure 1. Market Ecosystem
Figure 2. Secondary Sources referenced for this study
Figure 3. Primary Research Techniques
Figure 4. Key Executives Interviewed
Figure 5. Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6. Market Sizing & Growth Forecast Approach
Figure 7. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
Figure 8. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
Figure 9. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
Figure 10. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
Figure 11. Impact Analysis of Market Dynamics
Figure 12. USFDA regulatory pathways for cardiac biomarkers
Figure 13. EU regulatry pathway – IVDR 2017/746
Figure 14. China: medical device classification and premarket requirements for crdaiac biomarkers products
Figure 15. Porter’s Five Forces Analysis: cardiac biomarkers market
Figure 16. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
Figure 17. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
Figure 18. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
Figure 19. Global pharmaceutical R&D spending, 2012-2026 (USD Billion)
Figure 20. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
Figure 21. North America: Cardiac biomarkers Market Snapshot
Figure 22. U.S. population aged 65 years and above, 2022-2026 (million)
Figure 23. U.S.: cardiovascular diseases prevalence rate in the population, 2021-2035
Figure 24. Europe: Cardiac biomarkers Market Snapshot
Figure 25. Asia Pacific: Cardiac biomarkers Market Snapshot
Figure 26. Latin America: Cardiac biomarkers Market Snapshot
Figure 27. Middle East & Africa: Cardiac biomarkers Market Snapshot
Figure 28. Key Growth Strategies Adopted By Leading Players, 2021?2024
Figure 29. Cardiac biomarkers Market: Competitive Benchmarking, By Type
Figure 30. Cardiac biomarkers Market: Competitive Benchmarking, By Region
Figure 31. Cardiac biomarkers Market: Competitive Dashboard
Figure 32. Cardiac biomarkers Market: Market Share Analysis, By Key Players (2023)
Figure 33. F. Hoffman-La-Roche Ltd: Financial Snapshot (2023)
Figure 34. Bio-Rad Laboratories, Inc.: Financial SNAPSHOT (2023)
Figure 35. Abbott Laboratories: Financial Snapshot (2023)
Figure 36. Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 37. Siemens Healthineer AG: Financial Snapshot (2024)
Figure 38. Danaher Corporation: Financial Snapshot (2023)
Figure 39. bioMerieux SA: Financial Snapshot (2023)
FIGURE 40. Becton, Dickinson and Company: FINANCIAL SNAPSHOT (2024)
Figure 41. QuidelOrtho Corporation: FINANCIAL SNAPSHOT (2023)